Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells

Liu,Bin; Shi,Yufeng; Peng,Wending; Zhang,Qingyu; Liu,Jie; Chen,Nianping; Zhu,Runzhi

doi:10.3892/mmr.2016.5258

Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells

Authors:
- Bin Liu
- Yufeng Shi
- Wending Peng
- Qingyu Zhang
- Jie Liu
- Nianping Chen
- Runzhi Zhu
View Affiliations

Affiliations: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Published online on: May 12, 2016 https://doi.org/10.3892/mmr.2016.5258
Pages: 159-164
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diosmetin (Dio) is a major active component of flavonoid compounds. A previous study demonstrated that Dio exhibited anticancer activity and induced apoptosis in HepG2 human hepatoma cells via cytochrome P450, family 1-catalyzed metabolism. The present study observed that cell proliferation of HepG2 cells was inhibited by Dio treatment and tumor protein p53 was significantly increased following Dio treatment. Following addition of recombinant transforming growth factor‑β (TGF‑β) protein to Dio‑treated HepG2 cells, cell growth inhibition and cell apoptosis was partially reversed. These findings suggest a novel function for the TGF‑β/TGF‑β receptor signaling pathway and that it may be a key target of Dio‑induced cell apoptosis in HepG2 cells.

View Figures

View References

1	Yue QX, Liu X and Guo DA: Microtubule-binding natural products for cancer therapy. Planta Med. 76:1037–1043. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bitis L, Kultur S, Melikoglu G, Ozsoy N and Can A: Flavonoids and antioxidant activity of Rosa agrestis leaves. Nat Prod Res. 24:580–589. 2010. View Article : Google Scholar : PubMed/NCBI
3	Androutsopoulos VP and Spandidos DA: The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation. J Nutr Biochem. 24:496–504. 2013. View Article : Google Scholar
4	Rice-Evans CA, Miller NJ and Paganga G: Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 20:933–956. 1996. View Article : Google Scholar : PubMed/NCBI
5	Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A, Palatini P and Floreani M: Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet. 25:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
6	Obmann A, Werner I, Presser A, Zehl M, Swoboda Z, Purevsuren S, Narantuya S, Kletter C and Glasl S: Flavonoid C-and O-glycosides from the Mongolian medicinal plant Dianthus versicolor Fisch. Carbohydr Res. 346:1868–1875. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
8	Poon RT and Borys N: Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol. 7:937–945. 2011. View Article : Google Scholar : PubMed/NCBI
9	Androutsopoulos VP, Mahale S, Arroo RR and Potter G: Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep. 21:1525–1528. 2009.PubMed/NCBI
10	Androutsopoulos V, Wilsher N, Arroo RR and Potter GA: Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett. 274:54–60. 2009. View Article : Google Scholar
11	Androutsopoulos VP, Ruparelia K, Arroo RR, Tsatsakis AM and Spandidos DA: CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology. 264:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
12	Drabsch Y and ten Dijke P: TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
13	Busse A and Keilholz U: Role of TGF-β in melanoma. Curr Pharm Biotechnol. 12:2165–2175. 2011. View Article : Google Scholar : PubMed/NCBI
14	Heldin CH, Landström M and Moustakas A: Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol. 21:166–176. 2009. View Article : Google Scholar : PubMed/NCBI
15	Meulmeester E and ten Dijke P: The dynamic roles of TGF-β in cancer. J Pathol. 223:205–218. 2011. View Article : Google Scholar
16	Zhang Q, Liu J, Liu B, Xia J, Chen N, Chen X, Cao Y, Zhang C, Lu C, Li M and Zhu R: Dihydromyricetin promotes hepato-cellular carcinoma regression via a p53 activation-dependent mechanism. Sci Rep. 4:46282014.
17	Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang C, Li M, Bao S and Zhu R: Dihydromyricetin reduced Bcl-2 expression via p53 in human hepatoma HepG2 cells. PloS One. 8:e768862013. View Article : Google Scholar : PubMed/NCBI
18	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar
19	Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al: Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
20	Harvey AL: Natural products in drug discovery. Drug Discov Today. 13:894–901. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ciolino HP, Wang TT and Yeh GC: Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res. 58:2754–2760. 1998.PubMed/NCBI
22	Takeuchi H, Yokota A, Ohoka Y and Iwata M: Cyp26b1 regulates retinoic acid-dependent signals in T cells and its expression is inhibited by transforming growth factor-β. PloS One. 6:e160892011. View Article : Google Scholar
23	Nagaraj NS and Datta PK: Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs. 19:77–91. 2010. View Article : Google Scholar
24	Perrot CY, Javelaud D and Mauviel A: Insights into the transforming growth factor-β signaling pathway in cutaneous melanoma. Ann Dermatol. 25:135–144. 2013. View Article : Google Scholar : PubMed/NCBI
25	Speidel D: Transcription-independent p53 apoptosis: An alternative route to death. Trends Cell Biol. 20:14–24. 2010. View Article : Google Scholar
26	Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 71:5606–5610. 2011. View Article : Google Scholar : PubMed/NCBI
27	Lee JH, Gaddameedhi S, Ozturk N, Ye R and Sancar A: DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells. Cancer Res. 73:785–791. 2013. View Article : Google Scholar
28	Burmakin M, Shi Y, Hedström E, Kogner P and Selivanova G: Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI